United States · FDA National Drug Code directory
Risedronate Sodium
A source-listed medicine record.
Factual source checks only. This page is not a clinically reviewed monograph. Historical or discontinued records may be included; listing does not confirm approval, current availability or pharmacy stock.
Medicine identity
- Source reference
- 59762-0407_b7e3ea01-4634-467a-b087-3d52ef7af465
- Product NDC
- 59762-0407
- Form
- TABLET, DELAYED RELEASE
- Composition / generic term
- risedronate sodium
- Labeler
- Mylan Pharmaceuticals, Inc.
- Marketing category
- NDA AUTHORIZED GENERIC
- Marketing start / end (source format)
- 20180302
- Source listing expiry
- 20271231
Source-listed ingredients
- RISEDRONATE SODIUM HEMIPENTAHYDRATE — 30.1 mg/1
- RISEDRONATE SODIUM MONOHYDRATE — 4.9 mg/1
These values do not establish equivalence or a dose recommendation.
Packages
- 4 TABLET, DELAYED RELEASE in 1 DOSE PACK (59762-0407-4) · 59762-0407-4
Source and coverage
Open FDA National Drug Code directory →
Snapshot retrieved: 2026-09-17. This is the acquisition date, not a medical review date.
Clinical information, images and comparisons appear only when separately reviewed for this record. Coverage may be incomplete. Ask a pharmacist or clinician about your treatment.
Browse United States records →